目的 综合评价胰胆管合流异常（PBM）与胆囊癌发生的关系，为胆囊癌的预防提供更多、更准确的信息。 方法 计算机检索中国生物医学文献数据库（CBM）、中国期刊网（CNKI）、PubMed、EMBASE、万方等数据库，检索时间从1977年4月－2011年5月，并结合文献追溯的方法，收集国内外公开发表的关于PBM与胆囊癌关系的病例对照研究或队列研究，采用RevMan 5.0.25软件进行Meta分析。 结果 总计纳入文献8篇，其中3篇仅对比分析了PBM在胆囊癌患者与正常对照组中发生率的差异，2篇仅对比分析了胆囊癌在PBM患者与正常对照组中发生率的差异，而另外3篇文献则对这两种发生率的差异都进行了对比。Meta分析结果显示：胆囊癌患者中PBM的发生率明显高于正常对照组，差异有统计学意义[OR=7.41，95%CI（5.03，10.87），P＜0.000 01]；且PBM患者中胆囊癌的发生率明显高于正常对照组，差异有统计学意义[OR=17.67，95%CI（10.43，29.94），P＜0.000 01]。 结论 PBM是胆囊癌发生的高危因素，与胆囊癌的发生密切相关。
Objective To assess the effectiveness and safety of prulifloxacin in the treatment of urinary tract infection. Methods The double-blind, double dummy and randomized controlled method was adopted. One hundred and forty-four patients were randomized to the treatment group (prulifloxacin , 4 tablets, bid) and the control group (levofloxacin, 4 tablets, bid). The randomization code was produced by computer. The treatment duration for both groups was from 7 to 10 days. Results Data were analyzed on the basis of full analysis sets (FAS) and per-protocol (PP) analysis. The total improvement rates of the trial and control groups were 85.07% and 88.52% respectively by FAS analysis, and 90.48% and 91.53% respectively by PP analysis. There was no significant difference between the two groups in improvement rates (Pgt;0.05). Bacterial negative rates in the trial and control groups were 93.75% and 93.88% respectively by FAS analysis and 97.83% and 97.87% respectively by PP analysis. The results showed no statistical significance difference between the two groups in bacterial negative rates (Pgt;0.05). The adverse events in the prulifloxacin and levofloxacin groups were 2.80% and 5.60% respectively. Conclusion Prulifloxacin has the same clinical effectiveness as levofloxacin with a few toxic adverse effects in the treatment of urinary tract infection.